31 July 2018 - - Par Pharmaceutical, an operating company of Dublin, Ireland-based generics and specialty branded pharmaceutical company Endo International plc (NASDAQ: ENDP), has begun shipping an authorized generic version of Merck's Invanz (ertapenem for injection), the parent company said.
Endo's subsidiary, Endo Ventures Ltd., has entered into an exclusive US supply and distribution agreement with a subsidiary of Kenilworth, N.J.-based Merck and Co., Inc., allowing Par to launch and distribute an authorized generic of the product.
Endo International plc (NASDAQ: ENDP) delivers quality medicines to patients in need through excellence in development, manufacturing and commercialization.
Chestnut Ridge, NY-based Par Pharmaceutical, an operating company of Endo International plc, develops, manufactures and markets generic pharmaceutical products.
The company's portfolio includes sterile injectables, alternative dosage forms and many other differentiated products. Par is advancing a research and development pipeline of approximately 200 potential new products.